HC Wainwright Estimates Geron's Q3 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Geron in a research report issued on Tuesday, November 5th. HC Wainwright analyst E. Bodnar expects that the biopharmaceutical company will earn ($0.09) per share for the quarter. HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for Geron's current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron's FY2024 earnings at ($0.36) EPS and FY2025 earnings at ($0.23) EPS.

Other equities research analysts also recently issued research reports about the company. Scotiabank started coverage on Geron in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $6.00 price target on the stock. Leerink Partners initiated coverage on shares of Geron in a report on Monday, September 9th. They issued an "outperform" rating and a $7.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Geron in a report on Friday, August 9th. Leerink Partnrs raised shares of Geron to a "strong-buy" rating in a research report on Monday, September 9th. Finally, StockNews.com raised shares of Geron to a "sell" rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $7.05.

Geron Stock Up 1.2 %

Shares of NASDAQ GERN traded up $0.05 during mid-day trading on Wednesday, hitting $4.27. The company had a trading volume of 13,017,969 shares, compared to its average volume of 10,323,016. The company has a market capitalization of $2.57 billion, a PE ratio of -11.72 and a beta of 0.52. The business's 50-day simple moving average is $4.33 and its 200 day simple moving average is $4.30. Geron has a 1-year low of $1.64 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The business had revenue of $0.88 million during the quarter, compared to analyst estimates of $0.34 million. During the same quarter last year, the firm posted ($0.09) earnings per share. The business's revenue for the quarter was up 2941.4% compared to the same quarter last year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Darwin Global Management Ltd. purchased a new position in Geron in the second quarter valued at about $106,185,000. Farallon Capital Management LLC increased its stake in Geron by 124.6% in the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company's stock valued at $71,389,000 after purchasing an additional 9,342,000 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in Geron in the 1st quarter valued at approximately $8,250,000. Price T Rowe Associates Inc. MD raised its holdings in Geron by 999.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company's stock worth $6,815,000 after purchasing an additional 1,877,184 shares during the last quarter. Finally, Altitude Crest Partners Inc. purchased a new stake in Geron during the first quarter worth $5,054,000. Hedge funds and other institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.